NTRK 1,2,3 Rearrangements in Patients With Solid Tumors

NCT06780384 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2025-01-17

No results posted yet for this study

Summary

This study aims to evaluate the incidence of NTRK rearrangements in patients with solid tumors in Italy. Additionally, the study seeks to define the correlation between IHC and FISH testing and to simplify the assessment of NTRK rearrangements in patients with solid tumors.

Conditions

  • NTRK1/2/3 Fusion Gene Detection

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY
  • Federico Cappuzzo

    lead OTHER

Principal Investigators

  • Federico Cappuzzo, PI · Fondazione FORT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-05
Primary Completion
2025-05-31
Completion
2025-08-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06780384 on ClinicalTrials.gov